CD40LG and atherosclerosis: Taken together it remains unclear whether the pharmacological blockade of CD40(L) as a treatment method for atherosclerosis or other inflammatory diseases will be a viable strategy for the future due to the side effects observed previously, encompassing severe immunosuppression (CD40) or thromboembolisms (CD40L).